Current Partners

Nanotechnology Characterization Lab (NCL)/ National Cancer Institute (NCI): PDS Biotechnology Corporation has been selected as an affiliate of the NCL. The NCL is a collaboration between the NCI, Food and Drug Administration (FDA) and the National Institute of Standards and Technologies (NIST). The NCL’s goal is to select the most promising cancer nanotechnologies and work with the companies to get their products rapidly through regulatory submissions with the FDA at no cost to the selected companies. PDS is collaborating with the NCL to develop Versamune™ –HPV.

University of North Carolina, Chapel Hill: PDS has a sponsored research agreement with Dr. Leaf Huang’s laboratory at UNC to develop Versamune™ –HPV and Versamune™ –melanoma. Dr. Huang, a founder of PDS Biotechnology and member of the scientific advisory board, is the inventor of the Versamune™ technology. Significant progress in understanding the benefits and mechanism of action of the technology have resulted.